Cancer Antigen 15.3 Levels And Lymphocyte To Monocyte Ratio Of Breast Cancer Subjects receiving Chemotherapy In Umuahia, Nigeria
DOI:
https://doi.org/10.59652/aim.v3i2.579Keywords:
Cancer Antigen 15.3, Lymphocyte to Monocyte Ratio, Breast Cancer, ChemotherapyAbstract
Cancer Antigen 15.3 level (CA 15.3) is used to monitor response to breast cancer treatment and could also be used to survey disease recurrence after treatment of metastatic breast cancer. Lymphocyte-monocyte ratio (LMR), is a reflection of the hosts immunity and its degree of tumor progression. A low lymphocyte count and a high monocyte count indicates that there’s an elevated tumor burden and a poor prognosis for the subject.
Aim of the Study: This study is aimed at finding out the levels of Cancer Antigen 15.3 Level and Lymphocyte to monocyte ratio of breast cancer subjects receiving chemotherapy in Umuahia, Nigeria.
Materials and Methods: A total of 120 subjects were enrolled in this study. They were aged between 14 and 75 years. Of these 120 subjects, 60 were clinically diagnosed breast cancer subjects, while 60 were apparently healthy subjects. The age range of BRCA subjects were between 14 and 83, the stage of BRCA were from stage I to IV. The haematological parameters were carried out using the five-part Midray BC-5180 haematology analyzer manufactured by the Chinese Midray company. The determination of the CA15.3 levels was done with an Enzyme linked immunosorbent assay (ELISA) machine. The test kit that was used for this test procedure is AccuBind Elisa microwells CA 15-3.
Results: From this study, at p<0.05; there was statistically significant increase in WBC (9.3 ± 4.5 x109/L versus 6.8 ± 1.7x109 /L) (p=0.0001), monocyte (7.4 ± 1.8 % versus 3.3 ± 1.1 %)(<0.0001), mean platelet volume (9.0 ± 1.2 fl versus 8.1 ± 0.7 fl)(<0.0001), and CA 15-3 (23.2 ± 8.0 U/ml versus 9.3 ± 5.4 U/ml)(p=<0.0001) in Breast Cancer Patients when compared with control subjects also, significant statistical decrease was observed in eosinophils (1.5 ± 1.6% versus 2.1 ± 1.9%)(p=0.0413), basophils (0.1 ± 0.2 versus 0.5 ± 0.4)(p=<0.0001), RBC (3.5 ± 0.7 x1012/l versus 4.9 ± 0.6 x1012/l)(p=<0.0001), PCV (27.2 ± 6.4 % versus 35.9 ± 3.0 %)(p= <0.0001), PDW (13.5 ± 0.8 versus 17.0 ± 1.7)(p=<0.0001), HB (8.8 ± 2.1g/dl versus 11.9 ± 1.1g/dl)(p=<0.0001), MPV (9.0 ± 1.2fl versus 8.1 ± 0.7 fl)(p=<0.0001), LMR (4.4 ± 2.5 versus 7.7 ± 6.1)(p= 0.0002), in Breast Cancer Subjects, when compared with control subjects. As CA 15.3 is increased in cancer patients, lymphocyte- monocyte ratio LMR is decreased in cancer patients (r = -0.259(P = 0.046), (r=1.000) (p=0.000).
Conclusion: There was a negative correlation in cancer antigen 15.3 levels and lymphocyte monocyte ratio as the levels of CA 15.3 were increased while LMR levels were reduced. The subjects in this study had better survival outcomes at the 5th chemotherapy session.
Downloads
References
Simpson, P. T., Reis-Filho, J. S., Gale, T. & Lakhani, S. R. (2005). Molecular evolution of breast cancer. Journal of the Pathological Society of Great Britain & Ireland, 205, 248-254.
Kamangar, F., Dores, G. M. & Anderson, W. F. (2006). Patterns of cancer incidence, mortality and prevalence across five con-tinents: defining priorities to reduce cancer disparities in different geographic regions of the world. Journal of Clinical Oncology, 24(1), 2137-2150.
Godwin, A. E., Gabriel, U. U., Martin, A. N., Ima-Abasi, B., Victor, S. N. & Udosen, S. E. (2013). Histological type and tumour grade in Nigerian Breast Cancer, Relationship to menarche, Family History of Breast Cancer, parity, Age at first Birth and age at menopause. 10SR Journal of Dental and Medical Science, 7(2), 58-63.
Nggada, H. A., Gali, B. M., Bakari, A. A., Yawe, M. B., Tahir, E. A., Dahiru, A. B. & Yawe, K. D. T. (2011). The Spectum of female breast diseases among Nigerian population in Sehel Climatic Zone. Journal of Medicine and Medical Sciences, 2(10), 1157-1161.
Eniojukan, J. F & Adepoju, T. (2015). An Audit of the management and associated contextual correlates of clinical presentation of breast cancer in tertiary hospital in South West Nigeria. Journal of Pharmacy, 5(6), 11-21.
Ramaswamy, M. D., Yenni, G., Matthew, A., Arquetle, M. D. & Lieber, R. L. (2002). The Washington Manual of Oncology. Breast Cancer, 1(7), 13-47.
Schmidt, H., Bastholt, L., Geertsen, P., Christensen, I. J., Larsen, S., Gehl, J., von der Maase, H. (2005). Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. British Journal of Cancer, 93(3), 273–278.
Tibaldi, C., Vasile, E., Bernardini, I., Orlandini, C., Andreuccetti, M., Falcone, A. (2008). Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: a prognostic model. Journal of Cancer Research and Clinical Oncology, 134(10), 1143–1149.
Stotz, M., Pichler, M., Absenger, G., Szkandera, J., Arminger, F., Schaberl-Moser, R., Samonigg, H., Stojakovic, T. & Gerger, A. (2014). The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. British Journal of Cancer, 110(2), 435–440.
Noy, R., & Pollard, J. W. (2014). Tumor-associated macrophages: from mechanisms to therapy. Immunity, 41(1), 49–61.
Goto, W., Kashiwagi, S., Asano, Y., Takada, K., Takahashi, K., Hatano, T., Takashima, T., Tomita, S., Motomura, H., Hirakawa, K. & Ohira, M. (2018). Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer. BMC Cancer,18(1), 11-37.
Malati, T. (2007). Tumor markers: An overview. Indian Journal of Clinical Biochemistry, 22(2), 17-31.
Igbokwe, U. M., & Nwankwo, N. C. (2011). Geostatistical Correlation of Aquifer Potentials in Abia State, South-Eastern Ni-geria. International Journal of Geosciences, 2(1), 541-548.
Lin, E. Y. & Pollard, J. W. (2004). Role of infiltrated leucocytes in tumour growth and spread. British Journal of Cancer, 90(11), 2053–2058.
Qian, B. Z, & Pollard, J. W. (2010). Macrophage diversity enhances tumor progression and metastasis. Cell, 141(1), 39–51.
De Cock, L., Haylen, J., Wilders, A., Punie, K., Smeets, A., Weltens, C., Neven, P., Billen, J., Laenen, A & Wilders. H. (2021). Detection of secondary metastastatic breast cancer by measurement of plasma CA15.3. European Society for Medical Oncology, 6(4) 1-9.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Annals of Innovation in Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
